Biohaven BHV7000 Rise Focal Epilepsy Study
About the study?
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy.
Purpose of the study?
If you or a loved one have been diagnosed with focal onset epilepsy, are between the ages of 18-75 and are still experiencing seizures while taking one or more anti-seizure medications, you may qualify for the Rise study
BHV-7000 is a new type of medicine currently being studied to see if it can help people with focal onset epilepsy. This medicine works by targeting specific parts of brain cells called Kv7.2/Kv7.3 potassium ion channels. These channels are like tiny gates that help control the electrical signals moving through the brain. In people with epilepsy, these signals can sometimes become overactive and lead to seizures.
All participants who complete the double-blind phase of the study will have the opportunity to enroll in a separate long-term safety study where all participants will receive BHV-7000 and study-related care, at no cost.